Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Lincoff AM, et al. Semaglutide and cardiovascular outcomes in patients with obesity. N Engl J Med. 2023;389(23):2221–2232.
Ferrannini G, et al. Energy balance after SGLT2 inhibition. Diabetes Care. 2015;38(9):1631–1637.
Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
Harcha WG, et al. Dutasteride for male androgenetic alopecia: randomized, active- and placebo-controlled study. J Am Acad Dermatol. 2014;70(3):489–498.
Choi GS, et al. Long-term effectiveness and safety of dutasteride vs finasteride in male androgenetic alopecia. Ann Dermatol. 2022;34(6):441–449.
FDA. Dutasteride label—PSA considerations and precautions. 2011–2024.
Kim EH, et al. The use of 5-alpha reductase inhibitors in the treatment of BPH and prostate cancer. Investig Clin Urol. 2017;58(6):385–392.
Marihart S, et al. Dutasteride: a review of current data on a novel dual 5α-reductase inhibitor. Clin Interv Aging. 2005.
Nickel JC, et al. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6(Suppl 9):S31–S39.
Foyer CH, et al. The ascorbate–glutathione cycle: coming of age. J Exp Bot. 2024;75(9):2682–2699.
Sonthalia S, et al. Glutathione for skin lightening: a regnant myth or evidence-based verity? Dermatol Pract Concept. 2018;8(1):4–15.
Alzahrani TF, et al. Exploring the Safety and Efficacy of Glutathione: A Narrative Review. Cureus. 2025.
Pullar JM, et al. The Roles of Vitamin C in Skin Health. Nutrients. 2017;9(8):866.
DePhillipo NN, et al. Vitamin C supplementation and collagen synthesis: current concepts. 2018.
Wang SW, et al. Hemolysis attributed to high-dose vitamin C: case reports and literature review. World J Clin Cases. 2024;12(17):3168–3176.